XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Stock-based Compensation Expense
The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and nine months ended September 30, 2024 and 2023, respectively (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Research and development$87 $93 $260 $281 
General and administrative294 450 931 1,316 
Total stock-based compensation $381 $543 $1,191 $1,597 
Schedule of Stock Option Activity
The following table summarizes stock option activity of the Company for the nine months ended September 30, 2024:
Total
Number of
Shares
(In Thousands)		Weighted
Average
Exercise
Price		Weighted Average Remaining Contractual Term (In Years)Aggregate
Intrinsic
Value
(In Thousands)
Outstanding at December 31, 20231,607 $5.92 $— 
Granted671 0.53 
Canceled(325)3.53 
Outstanding at September 30, 20241,953 $4.47 7.91$425 
Options exercisable at September 30, 2024950 $7.17 7.00$— 
Schedule of Assumptions for Option Grants Issued
The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The weighted average assumptions used during the three and nine months ended September 30, 2024 and 2023, respectively, were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Risk free interest raten/an/a4.01 %3.78 %
Volatilityn/an/a130.41 %127.77 %
Expected lives (years)n/an/a6.196.20
Expected dividend yieldn/an/a— %— %
Schedule of RSU Activity
The following table summarizes RSU activity of the Company for the nine months ended September 30, 2024:

Shares
(In Thousands)		Weighted Average Grant Date Fair Value
Unvested at December 31, 2023338 $2.99 
Granted429 $0.52 
Canceled(123)$1.84 
Unvested at September 30, 2024644 $1.57